^
    Back
    Association details:
    Biomarker:PIK3CA mutation
    Cancer:Estrogen Receptor Positive Breast Cancer
    Drug:letrozole (Aromatase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Breast Cancer Res Treat
    Title:

    Induction of PIK3CA alterations during neoadjuvant letrozole may improve outcome in postmenopausal breast cancer patients

    Published date:
    08/03/2020
    Excerpt:
    An altered PIK3CA mutation profile from the pre- to the posttreatment specimen was significantly associated to improved pathological outcome. Overall and Disease-Free Survival benefits in PIK3CA mutated patients was observed. PIK3CA has the potential to be a predictive biomarker.
    DOI:
    10.1007/s10549-020-05833-w